The benefit of nebulized magnesium sulphate therapy in patients with acute severe asthma: a scoping review

In children acute severe asthma is a serious condition. The inhaled route for drug delivery is not appropriate when only small respiratory gas volumes are shifted; the i.v. route may be associated with greater side effects. Magnesium sulphate IV has a place in acute asthma management because it is a mild bronchodilator, and has a stabilizing effect on the atria. Objective: To compare the effectiveness of intravenous magnesium sulphate versus intravenous aminophylline in acute attack of asthma. Study Design: Randomized control trial. Setting: Emergency Department of pediatric Duration: April 2017 to October 2017.Material & Methods: 60 cases were included in the study. They were randomly divided in two comparable groups. Children in group A ware treated with intravenous magnesium sulphate and group B with intravenous aminophylline. The efficacy of the drug was judged by the improvement in the sign observed like respiratory rate (less than 40 per minute), pulse rate(<100), oxygen saturation( above 90 %) assessed after the time period of three hours. Results: Effectiveness of intravenous magnesium sulphate in acute attack of asthma was found in 28 cases in Group A (93.33%) and in 22 cases in Group B (73.33%) with p-value 0.03. However, 6.67% cases (2 cases) in Group A and 26.67% cases (8 cases) in Group B did not show effectiveness. Conclusion: The clinical efficacy of intravenous magnesium sulphate in managing case of acute severe asthma was better when compared with intravenous aminophylline.

Download Full-text

MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo-controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children

Health Technology Assessment ◽

10.3310/hta17450 ◽

2013 ◽

Vol 17 (45) ◽

Cited By ~ 20

Author(s):

CVE Powell ◽

R Kolamunnage-Dona ◽

J Lowe ◽

A Boland ◽

S Petrou ◽

...

Keyword(s):

Economic Evaluation ◽

Severe Asthma ◽

Magnesium Sulphate ◽

Controlled Trial ◽

Acute Severe Asthma ◽

Asthma In Children

Download Full-text

Intravenous magnesium sulphate as an adjuvant in acute severe asthma refractory to conventional therapy

Asian Journal of Medical Sciences ◽

10.3126/ajms.v6i1.9609 ◽

2014 ◽

Vol 6 (1) ◽

pp. 134-135

Author(s):

Aswini Kumar Sahoo ◽

SC Mohapatra

Keyword(s):

Severe Asthma ◽

Magnesium Sulphate ◽

Conventional Therapy ◽

Acute Severe Asthma ◽

Medical Sciences ◽

Intravenous Magnesium

DOI: http://dx.doi.org/10.3126/ajms.v6i1.9609 Asian Journal of Medical Sciences Vol.6(1) 2015 134-135

Download Full-text

Potentially (near) fatal asthma

Allergy and Asthma Proceedings ◽

10.2500/aap.2019.40.4257 ◽

2019 ◽

Vol 40 (6) ◽

pp. 403-405 ◽

Cited By ~ 1

Author(s):

Paul A. Greenberger

Keyword(s):

Severe Asthma ◽

Health Care Professionals ◽

Rescue Therapy ◽

Respiratory Acidosis ◽

Acute Severe Asthma ◽

Increased Risk ◽

High Risk Type ◽

Fatal Asthma ◽

Long Acting ◽

Near Fatal Asthma

Potentially (near) fatal asthma (PFA) defines a subset of patients with asthma who are at increased risk for death from their disease. The diagnosis of PFA should motivate treating physicians, health professionals, and patients to be more aggressive in the monitoring, treatment, and control of this high-risk type of asthma. A diagnosis of PFA is made when any one of the following are present: (1) a history of endotracheal intubation from asthma, (2) acute respiratory acidosis (pH < 7.35) or respiratory failure from acute severe asthma, (3) two or more episodes of acute pneumothorax or pneumomediastinum from asthma, (4) two or more episodes of acute severe asthma, despite the use of long-term oral corticosteroids and other antiasthma medications. There are two predominant phenotypes of near-fatal exacerbations: “subacute” exacerbation and “hyperacute” exacerbation. The best way to “treat” acute severe asthma is 3‐7 days before it occurs (i.e., at the onset of symptoms or change in respiratory function) and to optimize control of asthma by decreasing the number of symptomatic days and the days and/or nights that require rescue therapy and increasing baseline respiratory status in “poor perceivers.” PFA is treated with a multifaceted approach; physicians and health-care professionals should appreciate limitations of pharmacotherapy, including combination inhaled corticosteroid‐long-acting β-agonist products as well as addressing nonadherence, psychiatric, and socioeconomic issues that complicate care.

Download Full-text

Using routinely collected primary care records to identify and investigate severe asthma: a scoping review

npj Primary Care Respiratory Medicine ◽

10.1038/s41533-020-00213-9 ◽

2021 ◽

Vol 31 (1) ◽

Author(s):

Jonathan Stewart ◽

Frank Kee ◽

Nigel Hart

Keyword(s):

Primary Care ◽

High Risk ◽

Severe Asthma ◽

Scoping Review ◽

Asthma Severity ◽

Data Sources ◽

Full Potential ◽

High Risk Disease ◽

Asthma Outcomes ◽

Disease Variant

AbstractShielding during the coronavirus pandemic has highlighted the potential of routinely collected primary care records to identify patients with ‘high-risk’ conditions, including severe asthma. We aimed to determine how previous studies have used primary care records to identify and investigate severe asthma and whether linkage to other data sources is required to fully investigate this ‘high-risk’ disease variant. A scoping review was conducted based on the Arksey and O’Malley framework. Twelve studies met all criteria for inclusion. We identified variation in how studies defined the background asthma cohort, asthma severity, control and clinical outcomes. Certain asthma outcomes could only be investigated through linkage to secondary care records. The ability of primary care records to represent the entire known asthma population is unique. However, a number of challenges need to be overcome if their full potential to accurately identify and investigate severe asthma is to be realised.

Download Full-text